Today, the SVP Ops & Prod Dev of ANI Pharmaceuticals Inc (ANIP), James Marken, sold shares of ANIP for $345.7K.
Following James Marken’s last ANIP Sell transaction on December 21, 2015, the stock climbed by 24.4%. In addition to James Marken, 2 other ANIP executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on ANI Pharmaceuticals Inc’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $52.89 million and quarterly net profit of $440K. In comparison, last year the company earned revenue of $46.48 million and had a net profit of $2.24 million. ANIP’s market cap is $839.6M and the company has a P/E ratio of 60.89. Currently, ANI Pharmaceuticals Inc has an average volume of 145.2K.
Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $84.00, reflecting a 21.5% upside.
In the last 30 days, insiders have sold $517.1K worth of ANIP shares and purchased $173.2K worth of ANIP shares. The insider sentiment on ANI Pharmaceuticals Inc has been negative according to 33 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products.
